Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes: The SWITCH 2 Randomized Clinical Trial

What Was Tested

The paper reports a study of Insulin Glargine, published as a randomized controlled trial.

Who Took Part

The study group was 2015 adults.

By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, both men and women.

Randomized, double-blind, treat-to-target crossover trial including two 32-week treatment periods, each with a 16-week titration period and a 16-week maintenance period.

The trial was conducted at 152 US centers between January 2014 and December 2015 in 721 adults with type 2 diabetes and at least 1 hypoglycemia risk factor who were previously treated with basal insulin with or without oral antidiabetic drugs.

How the Study Was Run

The design is described as randomized, double-blind and crossover.

Because people in this Insulin Glargine study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the adults nor the staff measuring them knew who was on Insulin Glargine, so expectations could not easily colour the readings.

Each person switched between Insulin Glargine and the comparison at some point, usually with a gap in between.

What Was Measured

Topics PubMed links to this paper include Blood Glucose, Diabetes Mellitus, Type 2, Glycated Hemoglobin, Hypoglycemia, Hypoglycemic Agents, Insulin Glargine and Insulin, Long-Acting.

What This Means in Plain Language

The paper is a randomized, double-blind and crossover study of Insulin Glargine in 2015 adults.

With several hundred people or more, it is a fairly large study for this kind of research.

Results are reported in around 8 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2017 (JAMA), a journal based in United States.

More context: the Insulin Glargine compound page.